stoxline Quote Chart Rank Option Currency Glossary
Sensei Biotherapeutics, Inc. (SNSE)
0.7  0 (0%)    07-12 13:28
Open: 0.7
High: 0.7252
Volume: 13,320
Pre. Close: 0.7
Low: 0.6804
Market Cap: 18(M)
Technical analysis
2024-07-12 12:53:21 PM
Short term     
Mid term     
Targets 6-month :  0.87 1-year :  1.02
Resists First :  0.74 Second :  0.87
Pivot price 0.65
Supports First :  0.64 Second :  0.58
MAs MA(5) :  0.66 MA(20) :  0.64
MA(100) :  0.97 MA(250) :  0.89
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  72.8 D(3) :  55.9
RSI RSI(14): 50.2
52-week High :  1.94 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SNSE ] has closed below upper band by 2.1%. Bollinger Bands are 69.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.7 - 0.7 0.7 - 0.71
Low: 0.65 - 0.66 0.66 - 0.66
Close: 0.69 - 0.7 0.7 - 0.7
Company Description

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Headline News

Wed, 19 Jun 2024
Sensei Biotherapeutics Inc (SNSE) produces promising results - US Post News

Thu, 30 May 2024
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewswire

Fri, 24 May 2024
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? - InvestorPlace

Tue, 09 Apr 2024
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference - Yahoo Finance

Tue, 02 Apr 2024
RA Capital Management buys $49.95m of Eliem Therapeutics stock By -

Wed, 01 Nov 2023
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer - citybiz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 25 (M)
Shares Float 16 (M)
Held by Insiders 34.4 (%)
Held by Institutions 9.2 (%)
Shares Short 290 (K)
Shares Short P.Month 81 (K)
Stock Financials
EPS -1.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.32
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -24.9 %
Return on Equity (ttm) -41.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -28 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.6
PEG Ratio 0
Price to Book value 0.31
Price to Sales 0
Price to Cash Flow -0.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android